Novel.

Solutions.

Targeted.

Vaxiion has over 40 granted and pending patents with broad claims on bacterial minicell-based compositions and methods of use for targeted delivery of bioactive molecules and other life science applications. Stemming from 4 patent families, our intellectual property estate spans major markets including the United States, Europe, Australia, China, Japan, and S. Korea. 


​Granted patents include US 7,183,105;  US 7,396,822; US 8,129,166; US 7,871,815; US 8,101,396; US 8,524,484; US 9,017,986; US 9,045,761; US 9,267,108; EPO 2272946; EPO 2310502; AUS 2002318168; AUS 2008201082; AUS 2009262306; JP 5754648; CN 200980133155; KR 10-2011-7001928

Patents